Alterity Therapeutics Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Alterity Therapeutics has a total shareholder equity of A$13.8M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$19.2M and A$5.4M respectively.
Anahtar bilgiler
0%
Borç/özkaynak oranı
AU$0
Borç
Faiz karşılama oranı | n/a |
Nakit | AU$12.64m |
Eşitlik | AU$13.80m |
Toplam yükümlülükler | AU$5.43m |
Toplam varlıklar | AU$19.22m |
Son finansal sağlık güncellemeleri
Recent updates
Alterity launches phase 2 study of ATH434 for multiple system atrophy in UK
Aug 25Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy
Jul 06Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology
Sep 16Alterity Therapeutics names Dr. David Stamler as CEO
Jan 07Alterity and UniQuest partner to reverse bacterial resistance to antibiotics
Dec 21Alterity Therapeutics nabs US patent for compounds for neurodegenerative disorders
Nov 16Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: ATHE's short term assets (A$19.0M) exceed its short term liabilities (A$5.4M).
Uzun Vadeli Yükümlülükler: ATHE's short term assets (A$19.0M) exceed its long term liabilities (A$51.9K).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: ATHE is debt free.
Borcun Azaltılması: ATHE had no debt 5 years ago.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: ATHE has sufficient cash runway for more than a year based on its current free cash flow.
Tahmini Nakit Akışı: Insufficient data to determine if ATHE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.